Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Deepak Guttikonda

Vascular Surgery Indianapolis, IN Medical Doctor

NPI 1073542346 CMS profile 48088

8075 N Shadeland Ave Ste 330, Indianapolis, IN 46250

Open in the dashboard

General payments

$33,043

319 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Deepak Guttikonda of Indianapolis, IN is reported in the CMS Open Payments database as having received $33,043 across 319 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,064 50
2024 General $8,399 57
2023 General $5,863 72
2022 General $4,993 50
2021 General $4,193 43
2020 General $1,237 17
2019 General $2,294 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Deepak Guttikonda
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Deepak Guttikonda were reported at $6,064. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Deepak Guttikonda Vascular Surgery median Middle half National median
2019 $2,294 $796 $226–$2,363 $163
2020 $1,237 $348 $118–$1,110 $114
2021 $4,193 $471 $158–$1,421 $132
2022 $4,993 $725 $222–$2,183 $149
2023 $5,863 $836 $257–$2,440 $160
2024 $8,399 $909 $252–$2,619 $164
2025 $6,064 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $7,386 66 payments
  2. W. L. Gore & Associates, Inc. $5,768 60 payments
  3. Penumbra, Inc. $3,973 22 payments
  4. Philips Electronics North America Corporation $2,274 23 payments
  5. Reflow Medical Inc $2,081 15 payments
  6. Abbott Laboratories $1,716 21 payments
  7. Inari Medical, Inc. $1,683 7 payments
  8. Endologix, Inc. $1,484 12 payments
  9. Silk Road Medical, Inc. $1,363 11 payments
  10. Edwards Lifesciences Corporation $998 24 payments
  11. Other $4,318 58 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $31,410 316 payments
  2. Travel and Lodging $1,383 2 payments
  3. Consulting Fee $250 1 payment
Products named General payments · program years 2019–2025
  1. Indigo System $3,285 16 payments
  2. FLOWTRIEVER CATHETER, S $2,496 9 payments
  3. GORE VIABAHN VBX Balloon Expandable Endo $2,122 21 payments
  4. General - Vascular Intervention $1,519 12 payments
  5. ENROUTE Transcarotid Stent $1,363 11 payments
  6. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $1,363 11 payments
  7. CT THROMBECTOMY SYSTEM KIT $1,168 7 payments
  8. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $1,012 8 payments
  9. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $1,012 8 payments
  10. ENROUTE Transcarotid Neuroprotection System Enroute Nps 2.5 Plus - Pi $894 8 payments
  11. Other $19,561 222 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

847

Median for Vascular Surgery: 122

Drug cost

$165,212

Median for Vascular Surgery: $14,135

Branded share of claims

83.9%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 81 $91,825
Eliquis Apixaban Brand 58 $66,241
Clopidogrel Clopidogrel Bisulfate Brand 551 $5,702
Mupirocin Generic 78 $520
Enoxaparin Sodium Generic 11 $470
Atorvastatin Calcium Generic 20 $196
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 21 $150
Warfarin Sodium Generic 14 $94
Prednisone Generic 13 $15

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 90 billing codes

Paid by Medicare

$158,222

Medicare's payments for the services billed

Medicare patients

685

Average age 74

Services billed

1,210

326 women, 359 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 52%
Arthritis 52%
Chronic kidney disease 46%
Diabetes 44%
Heart failure 36%
COPD 31%
Depression 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

319 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record